Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CELC vs ABVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–2 Matrix Metrics)

ABVX Overall Winner 6-Pillar Tally: CELC 1 – 3 ABVX (2 Tie) Matrix Metrics: CELC 2 – 5 ABVX

As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELC carries a Unified Composite Score of 39.7/100 (SELL) at $61.31 (N/M Forward P/E, 0.0% operating margin), whereas ABVX carries 55.6/100 (HOLD) at $83.06 (N/M Forward P/E, -6270.4% operating margin).

  • Technical & Structure Timing Caution: CELC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELC vs ABVX
CELC NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$61.31
-4.75% 1D
Market Cap $3.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 60% Vol
Unified Composite Score
39.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 59.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 38
RSI-14: 38.5 · SMA20: $66.12 · SMA50: $71.78
ABVX NASDAQ Head-to-Head Winner
Abivax SA American Depositary Shares
Pharmaceutical Preparations
$83.06
-5.17% 1D
Market Cap $7.9B
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.38β · 48% Vol
Unified Composite Score
55.6 / 100 HOLD
Tech 42.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.1%), weak momentum, RSI 41
RSI-14: 40.5 · SMA20: $88.33 · SMA50: $94.23

6-Pillar Scorecard Institutional Category Breakdown (CELC 1 – 3 ABVX)

Columns: Metric · CELC · ABVX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABVX
Revenue Growth (YoY) +0.0% -6.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.7M
Market Cap $3.2B $7.9B
3. Profitability & Quality ABVX
Gross Margin N/A 100.0%
Operating Margin 0.0% -6270.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1192.9% -252.3%
4. Balance Sheet & Cash Flow CELC
Cash Generation (TTM) -$264M -$292M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $577M Net Debt $5.16 Book/Sh · -252.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 74.1% (30th %ile) 76.9% (<1st %ile)
Put/Call OI Skew 0.41x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELC (2) vs ABVX (5)
Institutional Metric CELC ABVX Criterion Row Edge
Market Capitalization
Scale
$3.2B $7.9B Larger Scale ABVX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -6.8% Higher Growth CELC
Operating Margin (TTM)
Profitability
0.0% -6270.4% Higher Margin CELC
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1192.9% -252.3% Higher ROE ABVX
52-Week Range Position
Momentum
8% ($54–$151) 17% ($70–$149) Stronger Trend ABVX
Beta / 30D Volatility
Risk Regime
1.28β · 60% Vol 1.38β · 48% Vol Lower Realized Risk ABVX
Unified Institutional Score
Composite Signal
39.7 / 100 (SELL) 55.6 / 100 (HOLD) Higher Composite ABVX
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$264M ($577M Net Debt) -$292M EBITDA ($5.16 Book/Sh · -252.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELC +14.12 pp
CELC: +8.36% · ABVX: -5.76%
3M Horizon ABVX +4.07 pp
CELC: -34.24% · ABVX: -30.17%
6M Horizon ABVX +26.76 pp
CELC: -53.62% · ABVX: -26.86%
1Y Horizon ABVX +11.02 pp
CELC: -28.71% · ABVX: -17.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELC vs ABVX. Trailing 12-month operating profitability (CELC 0.0% vs ABVX -6270.4%) and valuation multiples (CELC N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CELC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1192.9% · N/M
ABVX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin100.0%
Op. Margin-6270.4%
ROE / Fwd P/E-252.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELC BREAKDOWN
136d in phase · OBV DISTRIBUTION
Current IV 74.1%
IV Percentile 30th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CELC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.9B market capitalization and -6270.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELC vs ABVX Key Questions & Quantitative Answers

As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELC carries a Unified Composite Score of 39.7/100 (SELL) at $61.31 (N/M Forward P/E, 0.0% operating margin), whereas ABVX carries 55.6/100 (HOLD) at $83.06 (N/M Forward P/E, -6270.4% operating margin). Technical & Structure Timing Caution: CELC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVX leads the Growth & Scale pillar: CELC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, CELC generates N/A in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, CELC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.

CELC and ABVX trade at balanced relative valuation multiples. CELC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELC (-1192.9% ROE) versus ABVX (-252.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CELC carries 74.1% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.28β · 60% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.